## IN THE CLAIMS

Please amend the claims as follows:

Claims 1-9 (Canceled).

Claim 10 (Currently Amended): A method for treating [[a]] amyotrophic lateral sclerosis, which comprises:

administering to a subject in need thereof a cyclohexenone long-chain alcohol compound, pharmaceutically acceptable salt, solvate or hydrate thereof, represented by the following formula (1):

$$R^1$$
 $R^2$ 
 $X$ 
 $R^3$ 
 $R^3$ 

wherein each of R<sup>1</sup>, R<sup>2</sup>, and R<sup>3</sup> is a hydrogen atom or a methyl group; and X is a C15-C28 linear or branched alkylene group or a C15-C28 linear or branched alkenylene group to a patient in need thereof.

Claim 11 (Currently Amended): A method for treating amyotrophic lateral sclerosis caused by mutation in a superoxide dismutase gene, which comprises:

administering to a subject in need thereof a cyclohexenone long-chain alcohol compound, pharmaceutically acceptable salt, solvate or hydrate thereof, represented by the following formula (1):

Application No. 09/890,969 Reply to Office Action of August 24, 2005.

$$R^1$$
 $R^2$ 
 $X$ 
 $R^3$ 
 $R^3$ 

wherein each of R<sup>1</sup>, R<sup>2</sup>, and R<sup>3</sup> is a hydrogen atom or a methyl group; and X is a C15-C28 linear or branched alkylene group or a C15-C28 linear or branched alkenylene group to a patient in need thereof.

Claim 12 (Currently Amended): The method of claim 10, wherein X is a C15-C28 linear alkylene group the side chain of the branched alkylene or alkenylene group of X is a C1-C10 alkyl group.

Claim 13 (Currently Amended): The method of claim [[12]] 10, wherein X is a C15-C28 linear alkenylene group the alkyl-group is a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, an isobutyl group, a sec butyl group, a tert butyl group, a pentyl group, an isopentyl group, a neopentyl group, a tert pentyl group, a hexyl group, an isohexyl group, a heptyl group, an octyl group, a nonyl group, or a decyl group.

Claims 14-23 (Cancelled)

Claim 24 (Previously Presented): The method of claim 10, wherein the administering is orally, by injection or by suppository.

Claim 25 (Previously Presented): The method of claim 11, wherein the administering is orally, by injection or by suppository.

Application No. 09/890,969 Reply to Office Action of August 24, 2005.

Claim 26 (Previously Presented): The method of claim 10, wherein the daily dose for a human adult is 0.01-1000 mg.

Claim 27 (Previously Presented): The method of claim 11, wherein the daily dose for a human adult is 0.01-1000 mg.

Claim 28 (Previously Presented): The method of claim 10, wherein the daily dose for a human adult is 0.1-100 mg.

Claim 29 (Previously Presented): The method of claim 11, wherein the daily dose for a human adult is 0.1-100 mg.